Advanced Search

Solid Tumors Stocks List

Symbol Grade Name % Change
HALO A Halozyme Therapeutics, Inc. 1.09
ARGX A argenx SE 1.48
TPTX A Turning Point Therapeutics, Inc. 3.90
ANIX A Anixa Biosciences, Inc. -2.39
GRCL A Gracell Biotechnologies Inc. -3.83
INCY A Incyte Corporation 0.73
GNTA A Genenta Science S.p.A. 0.00
SGEN A Seattle Genetics, Inc. -2.10
IMMX A Immix Biopharma, Inc. 30.06
KNTE B Kinnate Biopharma Inc. 3.40
View As Page of Charts
Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Long-Term Care Facilities Medical Devices Other Shell Companies
Related Stock Lists: Cancer Biopharmaceutical Biotechnology Medicine Cancer Immunotherapy Gene Therapy Inflammation Lymphoma Autoimmune Disease Cancer Treatment Chemical Compounds Clinical Medicine Clinical Trial Product Hematologic Malignancies Immune System Janus Kinase Inhibitor Life Sciences Monoclonal Antibodies Nasdaq 100 Oncology

Related ETFs - A few ETFs which own one or more of the above listed Solid Tumors stocks.

Symbol Grade Name Weight
PBE B PowerShares Dynamic Biotech & Genome 9.71
GDOC B Goldman Sachs Future Health Care Equity ETF 9.21
BBP B BioShares Biotechnology Products Fund 7.96
BBH B Market Vectors Biotech ETF 7.3
FBT B First Trust Amex Biotech Index Fund 7.07
View all Solid Tumors ETFs...
Compare ETFs
Compare BBP to FBT Compare GDOC to FBT Compare PBE to BBH

Solid Tumors Stocks Recent News

Date Stock Title
May 21 IMMX We Think Immix Biopharma (NASDAQ:IMMX) Can Afford To Drive Business Growth
May 20 INCY CHMP Backs Approval of Lilly/Incyte's Olumiant For Patchy Hair Loss
May 20 INCY Eli Lilly Gets Positive Opinion for Olumiant in Europe. The Stock Rises.
May 20 SGEN Seagen (SGEN) Investor Presentation - Slideshow
May 20 IMMX ImmixBio's Lead Candidate Shows Improved Survival Over FDA-Approved Soft Tissue Cancer Drug
May 20 INCY Lilly, Incyte's Olumiant get EMA panel nod for hair loss disorder alopecia areata
May 20 IMMX ImmixBio surges on mice data for lead candidate in connective tissue cancer
May 20 IMMX ImmixBio stock surges on positive data from preclinical trial of soft tissue sarcoma treatment
May 20 IMMX ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study
May 20 INCY CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)
May 19 HALO Endo (ENDP) Crashes 46.54% as it Looks to Restructure Debt
May 19 HALO 5 Reasons Why You Should Add Halozyme (HALO) to Your Portfolio
May 19 GRCL Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
May 19 ARGX argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases
May 19 HALO Halozyme: Antares Pharma Bolsters Growth Prospects
May 18 ARGX argenx SE: Again Following Dutch Biotech, Prior Recommendation Near-Term Gain
May 18 INCY 2 Under-the-Radar Biotech Stocks to Buy in 2022
May 18 ANIX Anixa Biosciences (NASDAQ:ANIX) Is In A Strong Position To Grow Its Business
May 17 HALO Community Health (CYH) Boosts Obstetrics Care With Technology
May 16 GRCL Gracell Biotechnologies Inc. (GRCL) CEO Dr. William Cao on Q1 2022 Results - Earnings Call Transcript
Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Long-Term Care Facilities Medical Devices Other Shell Companies
Related Stock Lists: Cancer Biopharmaceutical Biotechnology Medicine Cancer Immunotherapy Gene Therapy Inflammation Lymphoma Autoimmune Disease Cancer Treatment Chemical Compounds Clinical Medicine Clinical Trial Product Hematologic Malignancies Immune System Janus Kinase Inhibitor Life Sciences Monoclonal Antibodies Nasdaq 100 Oncology

Browse All Tags